Search

The time-stability of the electrical characteristics of chalcogenide materials is one of the most important issues for their use in nonvolatile solid state memory applications. In particular the electrical conduction of the glassy phase evolves with time due to two different physical phenomena: the crystallization and the so-called low conductivity drift. Despite the physics of crystallization having been extensively studied in literature, the latter is mainly described by phenomenological relationships, and its physical comprehension is still under discussion. In this paper we study the amorphous phase low-field conductivity drift and its dependence on the temperature experienced by the device. We developed an experimental procedure able to separate the reversible change in the electrical conductivity with temperature due to the material semiconductorlike behavior from the nonreversible one related to the drift mechanism. A drift model explaining such nonreversible conductivity change as a band diagram modification is also provided and calibrated on experimental data. The present work finally introduces alternative metrics for drift quantification that can be useful in order to compare different materials. [ABSTRACT FROM AUTHOR]

A study on the amorphous glassy phase of [Ge.sub.2][Sb.sub.2][Te.sub.5] low-field conductivity drift and its dependence on the temperature experienced by the device is presented. The results provided a drift model to explain the conductivity change as a band diagram modification and introduced alternative metrics for drift quantification that could be applied to compare different materials.

The time-stability of the electrical characteristics of chalcogenide materials is one of the most important issues for their use in nonvolatile solid state memory applications. In particular the electrical conduction of the glassy phase evolves with time due to two different physical phenomena: the crystallization and the so-called low conductivity drift. Despite the physics of crystallization having been extensively studied in literature, the latter is mainly described by phenomenological relationships, and its physical comprehension is still under discussion. In this paper we study the amorphous phase low-field conductivity drift and its dependence on the temperature experienced by the device. We developed an experimental procedure able to separate the reversible change in the electrical conductivity with temperature due to the material semiconductorlike behavior from the nonreversible one related to the drift mechanism. A drift model explaining such nonreversible conductivity change as a band diagram modification is also provided and calibrated on experimental data. The present work finally introduces alternative metrics for drift quantification that can be useful in order to compare different materials. [ABSTRACT FROM AUTHOR]

Primary vascular tumors of bone are a heterogeneous group of neoplasms, ranging from benign hemangiomas to frankly malignant epithelioid hemangioendotheliomas and angiosarcomas. Over the years, their classification has been a matter of discussion, due to morphologic similarities and uncertainty regarding biologic behavior. Over the past decade, with the development of next-generation sequencing, there has been a significant improvement in the molecular characterization of these lesions. The integration of their morphologic, immunohistochemical and molecular features has led to a better stratification, with important prognostic and therapeutic implications. Nevertheless, primary vascular bone tumors still represent a challenge for medical oncologists. Given their rarity and heterogeneity, in the last few years, there has been no significant progress in medical treatment options, so further research is needed. Here we present a review of the current knowledge regarding primary vascular tumors of the bone, correlating clinicopathologic features with tumor behavior and therapeutic approaches., Competing Interests: Declaration of Competing Interest PR reports personal fees as Consultant for Exactech and Stryker. AB reports serving on advisory boards for Eli Lilly, Roche, GSK, Eisai, Pharmamar, Boehringer Ingelheim, Deciphera; personal fees or honoraria for educational events by GSK and Pharmamar; travel grants by Gentili and Pharmamar. All the authors, including PR and AB, declare no competing interests with respect to this research., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Background: Incidences of soft tissue sarcomas (STS) steadily increase with age. Yet, despite the high prevalence in advanced age, older patients (pts) are underrepresented in sarcoma clinical trials and evidence-based guidelines for chemotherapy are lacking. International oncological societies suggest using geriatric tools to evaluate older patients with cancer to optimise treatment indication. Comprehensive geriatric assessment (CGA) is a multidimensional assessment of older subjects, based on which pts can be classified as fit, vulnerable or frail. Onco-MPI (multidimensional prognostic index) is a CGA-based score which also considers tumour characteristics, classifying pts into three risk groups of death at one year: high-risk, intermediate-risk and low-risk. Methods: This is a single-centre retrospective study which aims at describing real-word management and outcomes of older pts with advanced stage STS and at assessing the ability of CGA and onco-MPI to predict survival in these pts. Consecutive pts with advanced stage STS aged 70 years or older and treated at the Istituto Oncologico Veneto from January 2009 to June 2020 were retrieved from a prospectively maintained database. Pts' demographics, CGA assessments and tumour characteristics were analysed. Statistical analysis was performed with R version 3.4.3 Results: Out of 101 pts, with a median age of 77 years, 76 received chemotherapy (75.3%), which was anthracycline-based for 46 pts (60.5%). Anthracyclines were used in a higher proportion in fit pts (58.9% fit vs. 45.1% vulnerable vs. 12.5% frail pts). Frail pts and pts in the onco-MPI high-risk group experienced a higher rate of chemotherapy-related toxicities. Median OS was 13.8 months (95% CI 11.3-17.7 months). According to CGA, the median OS was 19.53 months (95% CI 15.23-36.8) for fit pts, 12.83 months (95% CI 9.7-17.5) for vulnerable and 7.75 months (95% CI 2.73-30) for frail pts ( p = 0.005). Onco-MPI confirmed a predictive value for 1-year survival with intermediate risk pts not reaching a median OS at 1 year, and high-risk pts having a median one-year OS of 11.5 months (95%CI 9.7-NA), p = 0.02. In multivariate analysis, onco-MPI and CGA were associated with survival (high risk onco-MPI: HR 5.5, 95%CI 1.25-24.7 p = 0.02; fitness at CGA HR 0.552 95% 0.314-0.973; p = 0.040) as well as chemotherapy use (HR 0.24, 95% CI 0.11-0.51, p < 0.005). Conclusions: Both CGA and onco-MPI retain prognostic value for survival in pts with metastatic STS. Pts frail/vulnerable at CGA and pts within the onco-MPI high risk category should be offered an oncogeriatric management approach in order to optimise treatment-related survival and reduce toxicity.